Targeting Bcl-2 in Herceptin-Resistant Breast Cancer Cell Lines.
about
Autophagy and Apoptotic Crosstalk: Mechanism of Therapeutic Resistance in HER2-Positive Breast CancerRamentaceone, a Naphthoquinone Derived from Drosera sp., Induces Apoptosis by Suppressing PI3K/Akt Signaling in Breast Cancer CellsArtemin, a member of the glial cell line-derived neurotrophic factor family of ligands, is HER2-regulated and mediates acquired trastuzumab resistance by promoting cancer stem cell-like behavior in mammary carcinoma cells.Resistance to HER2-targeted therapies: a potential role for FOXM1.Bcl-2 family proteins in breast development and cancer: could Mcl-1 targeting overcome therapeutic resistance?Pharmacological strategies to overcome HER2 cross-talk and Trastuzumab resistance.Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy.Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast CancerAlterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancerNew developments in the treatment of HER2-positive breast cancerSurvival of HER2-Positive Breast Cancer Cells: Receptor Signaling to Apoptotic Control Centers.A new mechanism of trastuzumab resistance in gastric cancer: MACC1 promotes the Warburg effect via activation of the PI3K/AKT signaling pathwayPertuzumab : evolving therapeutic strategies in the management of HER2-overexpressing breast cancer.Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer.Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade.Predicting and Overcoming Chemotherapeutic Resistance in Breast Cancer.Pharmacological Inhibition of the Skeletal IKKβ Reduces Breast Cancer-Induced Osteolysis.Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers.Regulation of dual specificity phosphatases in breast cancer during initial treatment with Herceptin: a Boolean model analysis.Regulation of breast cancer induced bone disease by cancer-specific IKKβ.Bcl-2 promotes metastasis through the epithelial-to-mesenchymal transition in the BCap37 medullary breast cancer cell line.
P2860
Q26753162-A6DA3151-9799-41A8-9DB7-F9633CB091EAQ28553060-E68CE8BE-150F-4726-AC33-E3F57627FAFDQ33718457-A8D9A319-DBA2-4C62-8EF1-F32F5EFE7297Q34955355-85D75E37-D659-45F6-B05F-F04BC42C60BBQ35551802-C75FDA61-C288-437D-BA2E-79CDE24FC18EQ35803226-BCC586A6-3E96-4A7C-9295-93A35469D5EAQ36021424-1C39CCBC-2FCE-4D15-A28D-EFC6C50D539CQ36440214-9A3EC797-01C6-436B-8B7A-9C025AD92780Q36450457-0D856C1B-5549-4FEA-A1B6-6F7E66F78D9FQ37016382-90AAFA0C-98C8-4700-A96D-FAFD105376F4Q37194856-3A447DF7-A6EB-4256-B65F-1F2A2567ABA3Q37224355-ED901A23-F4F7-4DB7-8CDB-F1D0816C77C4Q38093224-DB00068A-BEA6-45E0-B4CA-10A4C2C28B5EQ38563530-458D4942-E53C-4482-B679-DB8D44D91AFAQ42503679-7DE9C745-53F2-4A9D-9E93-03AA3B0E2223Q49544395-0ADFEF38-B591-4E4A-BA4B-D71924060102Q49891124-9BA5E9CB-CCFA-4CFC-A1AF-473A4D2BE445Q49988930-37C5F540-1802-4874-BD49-72F02867AEA3Q52578585-03328396-45B7-4218-852A-F46E7FADF0D4Q52584355-F63F23AE-8A3D-4138-894A-E282E8BE0627Q55241008-48331D0F-86E3-44D9-B86A-C443371F3878
P2860
Targeting Bcl-2 in Herceptin-Resistant Breast Cancer Cell Lines.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Targeting Bcl-2 in Herceptin-Resistant Breast Cancer Cell Lines.
@ast
Targeting Bcl-2 in Herceptin-Resistant Breast Cancer Cell Lines.
@en
type
label
Targeting Bcl-2 in Herceptin-Resistant Breast Cancer Cell Lines.
@ast
Targeting Bcl-2 in Herceptin-Resistant Breast Cancer Cell Lines.
@en
prefLabel
Targeting Bcl-2 in Herceptin-Resistant Breast Cancer Cell Lines.
@ast
Targeting Bcl-2 in Herceptin-Resistant Breast Cancer Cell Lines.
@en
P2860
P1476
Targeting Bcl-2 in Herceptin-Resistant Breast Cancer Cell Lines.
@en
P2093
Anatasha Crawford
Rita Nahta
P2860
P304
P356
10.2174/187569211796957584
P577
2011-09-01T00:00:00Z